Latest Period
Q1 2026
Security Snapshot
ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT) Institutional Ownership
CUSIP: 77313F106
13F Institutional Holders and Ownership History from Q1 2018 to Q1 2026
Institutions Reporting
195
Shares (Excl. Options)
97,172,475
Price
$3.58
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- RCKT on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 97,172,475
- Total 13F value
- $347,762,169
- Portfolio coverage rank
- 0%
- Share change
- +5,282,410
- Value change
- +$19,692,779
- Number of holders
- 195
- Shares outstanding
- 109,265,652
- SEC-reported price per share
- $3.02
- Insider filing price
- $3.02
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock is tracked under CUSIP 77313F106.
- 195 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 183 to 195 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $320,068,446 to $347,762,169.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 195 institutions filings for Q1 2026.
Security key
77313F106
Latest holder period
Q1 2026
13F holders
195
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
RCKT full holder history
ROCKET PHARMACEUTICALS, INC. SEC filings
ROCKET PHARMACEUTICALS, INC. company facts
ROCKET PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 77313F106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
RCKT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MAVERICK CAPITAL LTD | 2.3% | -69% | $9,549,818 | -$22,232,671 | 2,513,110 | -70% | Maverick Capital, Ltd. | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.9% | -83% | $7,895,181 | -$48,317,346 | 1,004,476 | -86% | Wellington Management Group LLP | 30 May 2025 |
As of 31 Mar 2026, 195 institutional investors reported holding 97,172,475 shares of ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT). This represents 89% of the company’s total 109,265,652 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
74%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 16% | 17,687,772 | 0% | 0.63% | $63,322,224 |
| BlackRock, Inc. | 7.2% | 7,834,795 | -0.9% | 0% | $28,048,565 |
| CITIGROUP INC | 4.7% | 5,107,708 | -2.6% | 0.01% | $18,285,595 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.3% | 4,690,215 | 0% | 0% | $16,790,970 |
| STATE STREET CORP | 4.1% | 4,485,989 | +164% | 0% | $16,059,841 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 3,775,736 | 0% | 0% | $13,517,135 |
| MAVERICK CAPITAL LTD | 3.3% | 3,567,372 | +42% | 0.15% | $12,771,192 |
| Newtyn Management, LLC | 2.9% | 3,165,900 | +19% | 1.2% | $11,333,922 |
| Nuveen, LLC | 2.9% | 3,128,753 | +1880% | 0% | $11,200,936 |
| MILLENNIUM MANAGEMENT LLC | 2.9% | 3,118,124 | +75% | 0.01% | $11,162,884 |
| AQR CAPITAL MANAGEMENT LLC | 2.8% | 3,069,930 | +336% | 0.01% | $10,990,350 |
| MARSHALL WACE, LLP | 2.8% | 3,038,715 | +11433% | 0.01% | $10,878,600 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,189,256 | +3.3% | 0% | $7,839,361 |
| D. E. Shaw & Co., Inc. | 2% | 2,169,625 | -18% | 0.01% | $7,767,257 |
| Monaco Asset Management SAM | 1.9% | 2,058,303 | -31% | 2.3% | $7,368,725 |
| MORGAN STANLEY | 1.8% | 2,020,108 | -49% | 0% | $7,231,988 |
| GOLDMAN SACHS GROUP INC | 1.6% | 1,721,116 | +84% | 0% | $6,161,594 |
| UBS Group AG | 1.2% | 1,298,173 | +757% | 0% | $4,647,459 |
| TWO SIGMA INVESTMENTS, LP | 1% | 1,097,623 | -49% | 0% | $3,929,490 |
| FEDERATED HERMES, INC. | 0.94% | 1,023,747 | +16% | 0.01% | $3,665,014 |
| Point72 Asset Management, L.P. | 0.93% | 1,012,126 | +99% | 0.01% | $3,623,411 |
| Opaleye Management Inc. | 0.87% | 955,000 | 0% | 0.47% | $3,418,900 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.79% | 859,874 | -9% | 0% | $3,079,000 |
| JPMORGAN CHASE & CO | 0.73% | 796,224 | -46% | 0% | $2,742,991 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.66% | 724,392 | -2.7% | 0% | $2,593,323 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
33
Latest
Q1 2026
Rows shown
1-25 of 33
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 97,172,475 | $347,762,169 | +$19,692,779 | $3.58 | 195 |
| 2025 Q4 | 91,180,049 | $320,068,446 | -$17,903,135 | $3.51 | 183 |
| 2025 Q3 | 96,588,463 | $314,789,902 | +$10,465,360 | $3.26 | 171 |
| 2025 Q2 | 94,974,795 | $232,855,173 | -$147,581,517 | $2.45 | 194 |
| 2025 Q1 | 107,749,040 | $722,024,357 | -$52,696,378 | $6.67 | 233 |
| 2024 Q4 | 109,632,268 | $1,377,359,505 | +$161,902,372 | $12.57 | 222 |
| 2024 Q3 | 92,703,462 | $1,709,382,927 | +$19,027,944 | $18.47 | 189 |
| 2024 Q2 | 91,217,786 | $1,963,307,213 | -$33,485,873 | $21.53 | 176 |
| 2024 Q1 | 92,048,164 | $2,479,705,726 | +$111,013,838 | $26.94 | 183 |
| 2023 Q4 | 89,005,050 | $2,667,733,521 | -$7,076,901 | $29.97 | 192 |
| 2023 Q3 | 89,401,055 | $1,831,770,744 | +$255,347,743 | $20.49 | 174 |
| 2023 Q2 | 76,338,609 | $1,516,884,469 | -$31,879,301 | $19.87 | 162 |
| 2023 Q1 | 78,264,099 | $1,340,378,412 | +$44,795,861 | $17.13 | 161 |
| 2022 Q4 | 75,910,257 | $1,486,203,005 | +$147,925,718 | $19.57 | 167 |
| 2022 Q3 | 69,117,168 | $1,101,781,707 | +$65,989,396 | $15.96 | 159 |
| 2022 Q2 | 64,545,073 | $887,423,123 | +$4,039,525 | $13.76 | 141 |
| 2022 Q1 | 64,321,676 | $1,019,794,471 | +$10,531,491 | $15.86 | 142 |
| 2021 Q4 | 63,097,635 | $1,377,944,582 | +$9,053,118 | $21.83 | 141 |
| 2021 Q3 | 61,977,765 | $1,849,734,470 | -$24,640,220 | $29.89 | 142 |
| 2021 Q2 | 61,808,292 | $2,736,555,111 | -$11,025,172 | $44.29 | 144 |
| 2021 Q1 | 62,013,212 | $2,752,442,865 | -$22,930,130 | $44.37 | 169 |
| 2020 Q4 | 61,952,909 | $3,397,683,589 | +$431,615,785 | $54.84 | 172 |
| 2020 Q3 | 55,227,508 | $1,262,686,245 | +$19,995,693 | $22.86 | 124 |
| 2020 Q2 | 53,342,815 | $1,116,479,207 | +$14,452,216 | $20.93 | 113 |
| 2020 Q1 | 53,304,185 | $743,593,762 | +$12,202,337 | $13.95 | 102 |